Home  |  Contact

UniProtKB/Swiss-Prot O14773: Variant p.Gly284Val

Tripeptidyl-peptidase 1
Gene: TPP1
Variant information

Variant position:  284
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Glycine (G) to Valine (V) at position 284 (G284V, p.Gly284Val).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to medium size and hydrophobic (V)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CLN2; displays no residual enzyme activity; altered intracellular trafficking.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.

Sequence information

Variant position:  284
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  563
The length of the canonical sequence.

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.









Baker's yeast                 DERGET---------------LSHRLW-----LYAAPKRP-


Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

Chain 196 – 563 Tripeptidyl-peptidase 1
Domain 199 – 563 Peptidase S53
Active site 272 – 272 Charge relay system
Active site 276 – 276 Charge relay system
Glycosylation 286 – 286 N-linked (GlcNAc...) asparagine
Turn 284 – 286

Literature citations

Heterogeneity of late-infantile neuronal ceroid lipofuscinosis.
Zhong N.; Moroziewicz D.N.; Ju W.; Jurkiewicz A.; Johnston L.; Wisniewski K.E.; Brown W.T.;
Genet. Med. 2:312-318(2000)
Cited for: VARIANTS CLN2 GLN-127; VAL-284; ASN-428 AND ARG-473;

Identification of novel CLN2 mutations shows Canadian specific NCL2 alleles.
Ju W.; Zhong R.; Moore S.; Moroziewicz D.; Currie J.R.; Parfrey P.; Brown W.T.; Zhong N.;
J. Med. Genet. 39:822-825(2002)
Cited for: VARIANTS CLN2 MET-277; PRO-278; VAL-284 AND CYS-481;

Functional consequences and rescue potential of pathogenic missense mutations in tripeptidyl peptidase I.
Walus M.; Kida E.; Golabek A.A.;
Hum. Mutat. 31:710-721(2010)
Cited for: VARIANT CLN2 SER-544; CHARACTERIZATION OF VARIANTS CLN2 ARG-77; GLN-127; LEU-202; CYS-206; MET-277; VAL-284; SER-286; ASN-287; LYS-343; ARG-365; HIS-422; HIS-447; LEU-475 AND SER-544;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.